<DOC>
	<DOCNO>NCT01521546</DOCNO>
	<brief_summary>Duchenne muscular dystrophy ( DMD ) , common muscular dystrophy , lead skeletal cardiac muscle damage . Treatment pulmonary complication improve survival ; however , heart muscle disease cardiomyopathy emerge lead cause death , typically third decade . Although myocardial change begin early , clinically significant heart disease rarely detect first decade life . Consequently , DMD cardiomyopathy frequently go unrecognized ( untreated ) advance ( irreversible ) . Current DMD cardiovascular care guideline recommend beta-blockers angiotensin convert enzyme inhibitor ( ACEIs ) decrease ejection fraction ( EF ) note echocardiography ( echo ) ; however , strategy significantly improve outcomes . Our team recently make breakthrough mouse study , show model cause heart muscle disease human DMD add old medicine traditionally use high blood pressure late-stage heart failure actually prevent heart muscle damage . Because drug 's proven safety child adult , ready study immediately RCT patient DMD hopefully show , mouse , prevent devastate consequence heart muscle damage .</brief_summary>
	<brief_title>Eplerenone Subclinical Cardiomyopathy Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Duchenne Muscular dystrophy ( DMD ) deadly X-linked disease affect 1 3,500 male . DMD patient suffer significant disability due skeletal myopathy excess death due cardiomyopathy . Current guideline advocate initiate cardioprotective treatment evident global cardiac dysfunction , yet treatment paradigm improve survival much beyond third decade life . Potentially promising approach like gene therapy take considerable time improve outcome . Recently complete study DMD mouse model institution indicate exist drug know aldosterone antagonist , typically reserve advanced heart failure patient , preserve skeletal cardiac muscle function 80 % normal . Clinical study many center include show high-resolution , noninvasive cardiac magnetic resonance ( CMR ) detect subclinical myocardial fibrosis abnormal regional function prior global functional abnormality . Combining finding preclinical clinical study , plan execute randomize , control clinical trial ( RCT ) eplerenone plus background therapy vs. background therapy alone patient DMD . We expect aldosterone antagonist eplerenone compare standard therapy significantly delay progressive cardiomyopathy skeletal myopathy use highly reproducible image biomarkers select efficient sample size design , ultimately reduce disability death .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>DMD patient age 7 year old ( able complete cardiac MRI without sedation ) preserve left ventricular ( LV ) systolic function abnormal heart muscle late postgadolinium imaging ( LGE ) renal insufficiency ( GFR &lt; 40 mL/min/m2 ) nonMR compatible implant ( e.g . neurostimulator , AICD ) severe claustrophobia allergy gadolinium contrast prior use know allergy epleronone use potassiumsparing diuretic serum potassium level &gt; 5.0 mmol/L</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>cardiomyopathy</keyword>
	<keyword>aldosterone antagonist</keyword>
</DOC>